Research programme: adenosine A3 antagonists - Addex Pharmaceuticals

Drug Profile

Research programme: adenosine A3 antagonists - Addex Pharmaceuticals

Alternative Names: Adenosine A3 orthosteric antagonists - Addex

Latest Information Update: 14 Aug 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Therapeutics
  • Class
  • Mechanism of Action Adenosine A3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Glaucoma

Highest Development Phases

  • Discontinued Glaucoma

Most Recent Events

  • 16 Jul 2009 This adenosine A3 antagonist programme is available for licensing (http://addexpharma.com)
  • 16 Jul 2009 Discontinued - Preclinical for Glaucoma in Switzerland (unspecified route)
  • 29 Jan 2009 Preclinical trials in Glaucoma in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top